Almirall S.A. (OTCMKTS: LBTSF) is a Spanish pharmaceutical company headquartered in Barcelona, dedicated to the development, manufacture and commercialization of prescription medicines with a primary focus on dermatology, respiratory and internal medicine. Established in 1943, the company has built a robust pipeline through in-house research and strategic partnerships, advancing treatments that address conditions such as acne, psoriasis, atopic dermatitis and chronic obstructive pulmonary disease (COPD).
In dermatology, Almirall offers a range of therapeutic options including Oracea® (doxycycline for rosacea), Finacea® (azelaic acid foam for inflammatory lesions), and Skilarence® (dimethyl fumarate for plaque psoriasis), which have become mainstays in clinical practice. On the respiratory front, its portfolio features medicines such as Eklira® Genuair® (aclidinium bromide), a dual bronchodilator for COPD management, and the long-acting bronchodilator combination device Duaklir® Genuair®. The company’s commitment to internal medicine is exemplified by its work in multiple sclerosis, where it collaborates to bring forward treatments that aim to improve patients’ quality of life.
Almirall’s operations span Europe, North America and selected markets in Latin America and Asia, supported by manufacturing facilities in Spain and strategic collaborations with contract manufacturing organizations. The company maintains an active presence in research and development, with clinical trials underway in immunology and oncology, reflecting its ambition to diversify beyond dermatology while leveraging its regulatory expertise and global commercial footprint.
Under the leadership of Chief Executive Officer Jorge Gallardo, Almirall has pursued a balanced growth strategy, combining organic innovation with targeted acquisitions and licensing agreements. The company emphasizes sustainable practices and patient-centric approaches, aligning its organizational objectives with broader healthcare trends and regulatory priorities to reinforce its position as a specialist healthcare provider.
AI Generated. May Contain Errors.
Free LBTSF Stock Alerts